痛风门诊两种管理策略的真实世界比较研究
该研究比较了两个采用不同治疗策略的痛风门诊患者的结局。严格降尿酸策略组(目标血清尿酸≤0.30 mmol/L,早期联合促尿酸排泄药)与患者中心策略组在达到血清尿酸≤0.36 mmol/L及无痛风发作的比例上无显著差异,但严格策略组需要更多治疗强化。样本量小影响结果显著性。
要点
- 严格降尿酸策略与患者中心策略在尿酸达标和无发作比例上无显著差异。
- 严格策略组更多患者需要治疗强化,但不良事件数量无差异。
- 样本量小可能影响结果显著性,需谨慎解读。
核心结论
- 严格降尿酸策略使达到血清尿酸≤0.36 mmol/L且无痛风发作的患者比例非显著升高。
- 该结果伴随着显著更多的治疗强化。
- 样本量小对结果显著性有影响。
研究设计与样本
- 比较两个实施不同治疗策略的痛风门诊患者结局的对比研究。
- 纳入新诊断痛风且随访9-15个月的患者。
- 严格降尿酸策略组126例,患者中心策略组86例,平均随访时间分别为11.3±1.8个月和11.1±1.9个月。
主要发现
- 严格策略组83%(105/126)达到血清尿酸≤0.36 mmol/L,患者中心策略组74%(63/86),P=0.10。
- 严格策略组46%(58/126)无痛风发作,患者中心策略组36%(31/86),P=0.15。
- 严格策略组60%(76/126)使用别嘌醇单药治疗,患者中心策略组73%(63/86),P=0.05。
- 不良事件数量两组无差异(严格策略组25例[20%] vs 患者中心策略组20例[23%],P=0.55)。
- 调整混杂因素后关联无实质性改变。
关键数值与推荐
- 严格策略组设定血清尿酸目标≤0.30 mmol/L,并早期在所有患者中添加促尿酸排泄药至别嘌醇。
- 患者中心策略强调基于血清尿酸和患者对痛风控制满意度的共享决策。
- 共同主要结局为达到血清尿酸≤0.36 mmol/L且无痛风发作的患者比例。
临床怎么用
- 严格降尿酸策略可能提高尿酸达标和无发作比例,但需更多治疗强化。
- 患者中心策略可能减少治疗强化,但达标比例略低。
- 临床选择策略时应权衡治疗强化与患者偏好。
局限性
- 样本量小影响结果显著性。
- 非随机设计可能存在混杂因素。
- 随访时间9-15个月,长期结局未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare outcomes of 2 gout clinics that implemented different treatment strategies. METHODS: Patients newly diagnosed with gout and a follow-up of 9-15 months were included. Co-primary outcomes were the proportion of patients reaching a serum uric acid (UA) ≤0.36 mmoles/liter and free of flares. Secondary outcomes were the proportion of patients requiring treatment intensification and experiencing adverse events. One clinic adopted a strict serum UA (≤0.30 mmoles/liter target) strategy, with early addition of a uricosuric to allopurinol, and the other clinic adopted a patient-centered (PC) strategy emphasizing a shared decision based on serum UA and patient satisfaction with gout control. Independent t-tests or chi-square tests were used to test differences in outcomes, and logistic regressions were used to adjust the effect of the treatment center on outcomes for confounders. RESULTS: In total, 126 and 86 patients had a follow-up mean ± SD of 11.3 ± 1.8 versus 11.1 ± 1.9 months. In the UA strategy, 105 of 126 patients (83%) compared to 63 of 86 (74%) in the PC strategy (P = 0.10) reached the threshold of ≤0.36 mmoles/liter; and 58 of 126 (46%) versus 31 of 86 (36%) were free of flares (P = 0.15). In the UA strategy, 76 of 126 patients (60%) were on allopurinol monotherapy compared to 63 of 86 (73%) in the PC strategy (P = 0.05), yet the number of adverse events was not different (n = 25 [20%] versus n = 20 [23%]; P = 0.55). Adjusting for confounders did not substantially change these associations. CONCLUSION: A strict UA strategy resulted in a nonsignificantly higher proportion of patients reaching a serum UA ≤0.36 mmoles/liter and being free of flares. This result was accomplished with significantly more therapy intensification. The small sample size plays a role in the significance of results.
引用
- Te Kampe R, van Durme C, Janssen M, et al. Comparative Study of Real-Life Management Strategies in Gout: Data From Two Protocolized Gout Clinics. Arthritis Care Res (Hoboken). 2020. PMID: 31150161. doi:10.1002/acr.23995
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。